- Home
- IMCR vs MLKN Comparison
IMCR vs MLKN Comparison
Compare IMCR & MLKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCR | MLKN |
|---|---|---|
| Founded | 2008 | 1905 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Office Equipment/Supplies/Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2016 | 1994 |
Fundamental Metrics
Financial Performance| Metric | IMCR | MLKN |
|---|---|---|
| Price | $29.68 | $20.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $62.73 | N/A |
| AVG Volume (30 Days) | 364.8K | ★ 651.0K |
| Earning Date | 11-05-2026 | 09-22-2026 |
| Dividend Yield | N/A | ★ 3.71% |
| EPS Growth | 30.39 | ★ 344.44 |
| EPS | 0.23 | ★ 0.38 |
| Revenue | $249,428,000.00 | ★ $3,841,700,000.00 |
| Revenue This Year | $13.06 | $2.23 |
| Revenue Next Year | $8.12 | $4.25 |
| P/E Ratio | $132.78 | ★ $53.03 |
| Revenue Growth | ★ 43.05 | 4.68 |
| 52 Week Low | $27.56 | $13.77 |
| 52 Week High | $40.71 | $24.71 |
Technical Indicators
Market Signals| Indicator | IMCR | MLKN |
|---|---|---|
| Relative Strength Index (RSI) | 28.05 | 47.70 |
| Support Level | $27.66 | $19.12 |
| Resistance Level | $30.21 | $21.54 |
| Average True Range (ATR) | 1.17 | 0.86 |
| MACD | -0.20 | 0.03 |
| Stochastic Oscillator | 5.03 | 66.31 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.